Non-Alcoholic Steatohepatitis Treatment Market Size, Share and Forecast, 2026–2035

Non-Alcoholic Steatohepatitis Treatment Market Size & Forecast 2035

The global non-alcoholic steatohepatitis treatment market was valued at USD 1.52 billion in 2025 and is projected to reach USD 19.98 billion by 2035, expanding at a CAGR of 29.4% during 2026–2035. The market includes prescription revenue attributable to pharmacological treatment of non-alcoholic steatohepatitis, now termed metabolic dysfunction-associated steatohepatitis, or MASH. It covers disease-directed medicines, indication-attributable GLP-1 therapy and clinically used adjunct pharmacotherapy. Diagnostic tests, liver-transplant procedures and drugs prescribed only for unrelated diabetes or obesity treatment are excluded.

The market has shifted from off-label disease management to a multi-product commercial category. Rezdiffra, or resmetirom, established the first disease-directed treatment pathway for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Wegovy added an approved GLP-1 option in the United States, connecting liver treatment with weight reduction and cardiometabolic risk management. The next competitive phase will include fibroblast growth factor 21 analogues, dual and triple incretin agents, combination regimens and therapies intended for compensated cirrhosis.

Commercial growth will not be determined by disease prevalence alone. The addressable population depends on case finding, fibrosis staging, specialist referral, non-invasive-test thresholds, reimbursement rules and persistence on long-duration therapy. Drug manufacturers that improve the full identification-to-treatment pathway can expand the treated population faster than companies focused only on physician awareness.

Key Highlights

• The market is forecast to add USD 18.46 billion in annual revenue between 2025 and 2035 as diagnosis, access and therapeutic choice expand.
• Thyroid hormone receptor-beta agonists generated an estimated 63% of 2025 revenue, equal to USD 957.6 million, closely reflecting Rezdiffra’s first full commercial year.
• GLP-1 receptor agonists represented 24%, or USD 364.8 million, based on MASH-attributable use rather than total obesity and diabetes sales.
• Patients with F2–F3 fibrosis accounted for 68% of treatment revenue, or USD 1.03 billion, because current disease-directed labeling and specialist pathways concentrate on moderate-to-advanced noncirrhotic disease.
• North America led with 72%, equivalent to USD 1.09 billion, supported by earlier approval, specialist access and rapid Rezdiffra adoption.
• Specialty pharmacies handled 53% of market revenue, reflecting prior authorization, patient onboarding, refill management and adherence support.
• Combination therapy, compensated-cirrhosis treatment and non-invasive diagnosis represent the three largest commercial expansion routes through 2035.

From Silent Disease to a Treatable Commercial Pathway

First approvals changed the market structure

For years, MASH treatment centered on weight loss, diabetes control, vitamin E and pioglitazone, with no medicine approved specifically to improve the underlying liver disease. Resmetirom changed this model by giving hepatologists and gastroenterologists a disease-directed oral option for patients with F2–F3 fibrosis. Madrigal reported USD 958.4 million in 2025 Rezdiffra net sales and more than 36,250 patients receiving treatment at year-end. This performance provides a concrete commercial base for a market previously defined mainly by pipeline potential.

The addition of semaglutide introduced a different value proposition. Rather than acting only on liver-directed thyroid hormone signaling, the GLP-1 pathway addresses body weight and metabolic drivers that contribute to disease progression. The coexistence of liver-directed and systemic metabolic treatment is likely to encourage sequencing and combination strategies instead of a single winner-take-all market.

Diagnosis is the principal revenue gate

MASH is commonly asymptomatic until advanced disease, and many patients remain within primary-care, diabetes or obesity practices without formal fibrosis staging. Liver biopsy offers detailed histology but is invasive and unsuitable for broad population screening. Commercial expansion therefore depends on stepwise use of routine laboratory scores, elastography, imaging and blood-based fibrosis tests.

The practical challenge is not identifying every person with liver fat. Health systems must find patients whose fibrosis risk justifies specialist review and prescription treatment. Referral pathways that begin with FIB-4 or another low-cost risk assessment and escalate selected patients to elastography can improve yield. Fragmented ownership between primary care, endocrinology, obesity medicine and hepatology can still delay treatment even after an abnormal result is available.

Specialist capacity constrains near-term uptake

Current prescribing is concentrated among hepatologists and gastroenterologists, although endocrinologists manage a large population with overlapping type 2 diabetes and obesity. Madrigal’s expansion of its endocrinology field force reflects the commercial need to move treatment beyond liver specialists. Broader prescribing can enlarge the funnel, but it also requires clear rules for confirming fibrosis stage, monitoring response and deciding when a hepatology referral remains necessary.

Access programs must manage prior authorization, clinical documentation, non-invasive-test evidence and safety monitoring. A medicine may be covered at the plan level yet remain difficult to start if a clinic lacks staff to complete benefit verification or appeals. Specialty-pharmacy services, electronic authorization support and patient assistance therefore have a direct effect on realized revenue.

Persistence will shape lifetime value

MASH is a chronic disease, and sustained treatment may be needed to maintain histological and metabolic improvements. Discontinuation caused by gastrointestinal adverse events, tolerability, cost, injection burden or weak patient understanding can reduce real-world effectiveness. In July 2026, Madrigal reported more than 49,000 patients on Rezdiffra and trailing-12-month sales close to USD 1.3 billion, demonstrating strong early uptake. Longer follow-up will determine how initiation converts into durable persistence.

The market is moving toward objective response monitoring. Liver stiffness, fibrosis biomarkers, lipid parameters, weight and glycemic measures can support continuation decisions, but thresholds are not yet uniform. Manufacturers that pair therapy with simple monitoring algorithms can give physicians and payers a clearer basis for assessing value.

Combination regimens create the next commercial layer

MASH biology includes steatosis, metabolic dysfunction, inflammation, cell injury and fibrosis. A single mechanism may not adequately address every component or every disease stage. Combination development is therefore moving toward pairing a liver-directed backbone with a metabolic or antifibrotic agent. Madrigal began Phase 1 dosing of its oral GLP-1 candidate MGL-2086 in June 2026 as part of a planned combination strategy with Rezdiffra.

FGF21 analogues, including efruxifermin and pegozafermin, offer a different route by targeting liver fat, insulin sensitivity and fibrosis biology. If late-stage trials succeed, injectable FGF21 products could compete in patients who need stronger fibrosis improvement or complement oral and incretin therapies. Combination development will increase clinical differentiation but may also raise treatment cost and evidence requirements.

Reimbursement will become more selective as options expand

Payers are balancing a large potentially eligible population against the need to prevent expensive cirrhosis, liver cancer and transplantation. Early access criteria frequently focus on confirmed F2–F3 fibrosis because disease progression risk is higher and approval evidence is strongest. As more drugs enter the market, formularies may distinguish patients by fibrosis stage, diabetes status, obesity, cardiovascular risk, route preference and prior treatment response.

Outcomes data will matter more than short-term liver-fat reduction. Demonstrating fewer decompensation events, hospitalizations, transplants or deaths can support premium pricing and earlier treatment. Conversely, medicines supported only by surrogate improvement may face step therapy or narrower eligibility once competitors provide broader clinical evidence.

Non-Alcoholic Steatohepatitis Treatment Market Scope

Market Segmentation

By drug class

Thyroid hormone receptor-beta agonists led with 63% of 2025 revenue, equal to USD 957.6 million. Rezdiffra established this segment through a once-daily, liver-directed mechanism that reduces liver fat and improves key MASH histology endpoints. The category’s near-term share reflects first-mover advantage, an established specialist commercial infrastructure and use in noncirrhotic F2–F3 disease.

GLP-1 receptor agonists represented 24%, or USD 364.8 million. The estimate includes only revenue attributable to MASH treatment, not the much larger volume prescribed for obesity or diabetes. The segment is positioned to gain share because it addresses weight, glycemic control and cardiovascular risk alongside liver outcomes. Adoption will depend on coverage, treatment supply, gastrointestinal tolerability and coordination between liver and metabolic specialists.

Insulin sensitizers, including pioglitazone, contributed 7%, equal to USD 106.4 million. Their low acquisition cost and long clinical history preserve use in selected patients with type 2 diabetes, but weight gain, safety considerations and the availability of approved alternatives limit premium growth. Vitamin E, lipid-modifying agents and other adjunct therapies accounted for 6%, or USD 91.2 million.

FGF21 analogues, pan-PPAR agonists and other investigational antifibrotic mechanisms generated no material commercial revenue in 2025 but represent a major forecast category once approved. Their eventual share will depend on fibrosis efficacy, dosing frequency, tolerability and positioning against established oral and GLP-1 therapies.

By fibrosis stage

F2–F3 disease accounted for 68% of 2025 revenue, totaling USD 1.03 billion. This segment aligns with the principal commercial population for approved disease-directed treatment: patients with moderate-to-advanced fibrosis who have not progressed to cirrhosis. Revenue is concentrated because these patients face materially higher liver-related risk and are more likely to be managed by specialists.

F0–F1 disease represented 18%, or USD 273.6 million. Treatment in early disease is centered on metabolic risk reduction and selected off-label therapies rather than liver-specific prescription medicine. Its revenue share can rise if future labels support earlier intervention, but broad treatment will require risk stratification to avoid medicating large numbers of low-progression patients.

Compensated and decompensated cirrhosis, classified as F4, generated 14%, equal to USD 212.8 million, mainly through supportive and metabolic management rather than approved antifibrotic therapy. This stage carries substantial unmet need. Successful outcomes trials in compensated MASH cirrhosis could create a high-value segment, while decompensated disease will remain clinically difficult because of safety risks and limited hepatic reserve.

By route of administration

Oral therapies held 76% of the market, or USD 1.16 billion, in 2025. Rezdiffra, pioglitazone, vitamin E and other oral medicines support this lead. Once-daily administration fits chronic therapy, but adherence still depends on perceived benefit, monitoring and affordability.

Injectable therapies accounted for 24%, equal to USD 364.8 million, driven by MASH-attributable semaglutide use. This share is expected to expand as GLP-1 and FGF21 therapies gain indications, although oral incretin development could shift part of the market back toward tablets.

By distribution channel

Specialty pharmacies generated 53% of 2025 revenue, totaling USD 805.6 million. They manage benefit verification, prior authorization, patient education, financial assistance and refill coordination for high-cost branded therapy. Their data can also help manufacturers identify abandonment points between prescription and treatment start.

Hospital and clinic pharmacies held 27%, or USD 410.4 million, supported by specialist centers and integrated health systems. Retail and mail-order pharmacies accounted for 20%, equal to USD 304.0 million, with a stronger role in generic adjunct therapy and broad metabolic treatment.

By prescriber type

Hepatologists and gastroenterologists represented 61% of 2025 revenue, or USD 927.2 million, because fibrosis confirmation and liver-specific treatment are concentrated in specialist practice. Endocrinologists and obesity-medicine physicians accounted for 23%, or USD 349.6 million. Primary-care physicians generated 10%, or USD 152.0 million, while cardiologists and other prescribers represented 6%, or USD 91.2 million. Expansion beyond hepatology will be a central driver, but safe growth requires standardized referral and monitoring protocols.

Regional and Country-Level Analysis

North America

North America generated 72% of global 2025 revenue, equal to USD 1.09 billion. The region benefited from the earliest resmetirom launch, strong specialty-pharmacy infrastructure and high diagnosis activity among liver specialists. The United States represented 68% of global revenue, or USD 1.03 billion. Its leadership reflects Rezdiffra’s first full year of sales, Wegovy’s MASH indication and a concentrated commercial focus on patients with F2–F3 fibrosis. Canada contributed 3%, or USD 45.6 million, while Mexico held 1%, or USD 15.2 million.

Europe

Europe accounted for 18% of the market, totaling USD 273.6 million. Germany led with 5% of global revenue, or USD 76.0 million, following the European launch of Rezdiffra and its established specialist infrastructure. The United Kingdom represented 3.5%, or USD 53.2 million, while France contributed 3%, or USD 45.6 million. Italy held 2.5%, or USD 38.0 million, and the rest of Europe generated 4%, or USD 60.8 million. Country-level growth depends on health-technology assessment, negotiated pricing, fibrosis-confirmation requirements and regional access to elastography.

Asia-Pacific

Asia-Pacific represented 8% of 2025 revenue, equal to USD 121.6 million. Japan generated 2.5% globally, or USD 38.0 million, supported by specialist liver care and substantial metabolic disease burden. China accounted for 2%, or USD 30.4 million, while South Korea held 1.2%, or USD 18.2 million. Australia contributed 1%, or USD 15.2 million, India represented 0.8%, or USD 12.2 million, and the rest of Asia-Pacific generated 0.5%, or USD 7.6 million. The region’s long-term potential is large, but treatment revenue is constrained by underdiagnosis, varied reimbursement and uneven access to fibrosis assessment.

Latin America

Latin America captured 1.2% of global revenue, or USD 18.2 million. Brazil accounted for 0.6%, equal to USD 9.1 million, and Mexico is included within North America for this report. Argentina, Colombia, Chile and other markets contributed the remaining USD 9.1 million. Obesity and diabetes create a substantial disease pool, but specialist access and affordability restrict branded-treatment uptake.

Middle East and Africa

The Middle East and Africa held 0.8%, or USD 12.2 million. Gulf countries accounted for 0.4% globally, or USD 6.1 million, while Israel represented 0.2%, or USD 3.0 million. South Africa and other markets contributed 0.2%, or USD 3.0 million. High metabolic risk in parts of the Middle East supports future demand, but consistent screening and reimbursement pathways remain underdeveloped.

Competitive Landscape

The commercial market is currently concentrated because approved disease-directed options are limited. Madrigal holds a strong first-mover position through Rezdiffra, while Novo Nordisk brings the scale of the Wegovy franchise and a treatment model spanning obesity, cardiovascular risk and MASH. Competition is expected to broaden through Novo Nordisk’s efruxifermin, Roche’s pegozafermin, Boehringer Ingelheim and Zealand Pharma’s survodutide, and multiple oral or injectable pipeline assets.

The principal competitive questions are shifting from whether a drug improves MASH histology to how it fits a patient pathway. Differentiation will depend on fibrosis-stage coverage, weight effect, cardiovascular profile, route, dosing frequency, adverse events, non-invasive monitoring and hard outcomes. Commercial strength will also require access teams capable of navigating specialty-pharmacy onboarding and payer documentation.

Madrigal Pharmaceuticals, Inc.

Madrigal is the current commercial leader through Rezdiffra, a once-daily oral thyroid hormone receptor-beta agonist approved for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. The company reported USD 958.4 million in 2025 net sales, with more than 36,250 patients on treatment at year-end. By June 30, 2026, the treated population exceeded 49,000, and second-quarter net sales reached USD 364.3 million.

The company is extending its strategy beyond a single medicine. Its pipeline includes compensated-cirrhosis development, an oral GLP-1 candidate designated MGL-2086, an oral DGAT2 inhibitor, siRNA programs and combination regimens anchored by Rezdiffra. This approach aims to preserve Rezdiffra as a treatment backbone as competing mechanisms enter the market. Commercial investment in endocrinology outreach and disease education targets the diagnostic bottleneck outside hepatology.

Novo Nordisk A/S

Novo Nordisk participates through Wegovy, or semaglutide, which received a United States indication for MASH in 2025. The product combines liver benefit with weight reduction and established cardiovascular evidence, creating a differentiated proposition for patients with obesity and cardiometabolic risk. Novo Nordisk’s global obesity sales infrastructure, payer relationships and manufacturing scale give it reach beyond liver-specialist practices.

The company strengthened its MASH pipeline through the acquisition of Akero Therapeutics and its Phase 3 asset efruxifermin. Efruxifermin is an FGF21 analogue designed to address metabolic and fibrotic disease biology. This creates potential for a portfolio spanning an approved incretin and a future antifibrotic injectable. The company’s 2026 scientific activity has emphasized a multisystem approach to MASH rather than treating liver histology in isolation.

F. Hoffmann-La Roche Ltd

Roche entered late-stage MASH development through its acquisition of 89bio. The principal asset, pegozafermin, is an engineered FGF21 analogue in Phase 3 studies for MASH with advanced fibrosis, including compensated cirrhosis. Its glycoPEGylated design is intended to extend half-life while retaining biological activity. Roche identifies pegozafermin as a high-potential cardiometabolic pipeline asset and is evaluating future combinations with incretin therapy.

Roche can combine pharmaceutical development with diagnostics, an important advantage in a disease where case finding and treatment selection depend on fibrosis assessment. The commercial opportunity will depend on late-stage efficacy, safety, dosing convenience and the ability to define where FGF21 treatment fits relative to oral THR-beta therapy and GLP-1 medicines.

Boehringer Ingelheim International GmbH

Boehringer Ingelheim is developing survodutide with Zealand Pharma. The compound is a dual glucagon and GLP-1 receptor agonist intended to combine weight loss with direct metabolic effects relevant to the liver. The program has advanced into Phase 3 development for MASH and obesity. Its competitive potential rests on whether the glucagon component produces meaningful liver-fat and fibrosis benefits beyond weight reduction alone.

The company brings global cardiometabolic development experience and established relationships in diabetes and cardiovascular medicine. A successful MASH program could position survodutide across multiple specialties, including endocrinology, obesity medicine and hepatology. The main commercial tests will be gastrointestinal tolerability, injectable-treatment persistence, fibrosis outcomes and differentiation in a rapidly crowded incretin market.

Recent Developments

• July 30, 2026 – Madrigal Pharmaceuticals: Madrigal reported second-quarter Rezdiffra net sales of USD 364.3 million, up 71% year over year, and more than 49,000 patients on treatment as of June 30. The company also disclosed three new resmetirom patents covering label-related use and compensated-cirrhosis treatment methods.
• June 2026 – Madrigal Pharmaceuticals: The first healthy volunteers were dosed in a Phase 1 single-ascending-dose study of MGL-2086, an oral GLP-1 receptor agonist intended for combination development with Rezdiffra. The program targets a once-daily oral regimen that addresses liver-directed and metabolic disease drivers.
• May 2026 – Novo Nordisk: At the European liver congress, Novo Nordisk presented analyses from its semaglutide program and promoted a multisystem treatment model linking hepatic disease with obesity, type 2 diabetes and cardiovascular risk. The strategy supports broader collaboration between hepatology and metabolic-care specialties.
• April 2026 – Boehringer Ingelheim: The company’s Phase 3 survodutide program continued enrolling adults with MASH and fibrosis through parallel late-stage studies. The trials are designed to evaluate a dual glucagon/GLP-1 mechanism in patients with clinically significant liver disease and will help define whether metabolic weight-loss therapy can deliver durable fibrosis benefit.

Strategic Takeaways

• Build the diagnosis pathway before expanding promotion. Fibrosis risk identification, elastography access and specialist referral determine the treatable population more directly than broad disease prevalence.
• Differentiate by fibrosis stage. F2–F3 disease is the current commercial center, while compensated cirrhosis offers the largest high-risk expansion opportunity.
• Prepare for combination treatment. Liver-directed, incretin and antifibrotic mechanisms are likely to be paired where one therapy does not address weight, inflammation and fibrosis together.
• Extend prescribing beyond hepatology carefully. Endocrinologists and obesity specialists can accelerate case finding, but they need standardized staging, referral and monitoring protocols.
• Treat persistence as a commercial metric. Long-term revenue depends on refill continuity, tolerability management and visible response, not prescription starts alone.
• Link price to avoided liver outcomes. Evidence on cirrhosis progression, decompensation, transplantation and mortality will carry more payer weight than liver-fat reduction by itself.
• Localize access strategies. Country-level reimbursement, diagnostic capacity and specialist availability differ sharply, requiring separate launch models for the United States, Europe and Asia-Pacific.

Why Purchase the Report?

· Visualize the composition of the global NASH (Non-alcoholic Steatohepatitis) Treatment Market across each indication, in terms of Type and Application options, highlighting the key commercial assets and players.

· Identify commercial opportunities in the global NASH (Non-alcoholic Steatohepatitis) Treatment Market by analyzing trends and co-development deals.

· Excel data sheet with thousands of data points of the global NASH (Non-alcoholic Steatohepatitis) Treatment Market - level 4/5 segmentation.

· PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

· Type mapping in excel for the key Services of all major market players

Target Audience:

· Equipment Suppliers/ Buyers

· Type Providers/ Buyers

· Industry Investors/Investment Bankers

· Education & Research Institutes

· Research Professionals

· Emerging Companies

· Manufacturers

Trending Topics

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market

Hepatitis Diagnostic Testing Market